Acridine ester chemiluminescence quantitative immunoassay assists the diagnosis of HBV

On this year’s World Hepatitis Day, "MORNING NEWS" reported a series of astonishing numbers: Hepatitis B and C affect 325 million people worldwide. At present, there are about 70 million hepatitis B virus carriers in China, and about 2-3 million need treatment, and among them only 18% can be diagnosed. These data show that the prevention and treatment of Hepatitis B is still a big challenge.

Early screening and diagnosis are the key to effective control of hepatitis B infection. HBsAg is the first serum marker to appear after hepatitis B virus infection and it is currently the most clinically used serum marker, and it is also a key indicator recognized by WHO to judge HBV infection. High sensitivity, high specificity, and quantitative detection are the three major trends in HBsAg detection. Acridine ester chemiluminescence immunoassay has the characteristics of simple luminescence system, no catalyst, high sensitivity and few interference factors. It is widely used in the diagnosis of tumor markers, infectious diseases, especially viral hepatitis.

Ou Saiying, Pan Yangbin and others [1] established a method for detecting the content of HBsAg in human serum/plasma based on the principle of chemiluminescence immunoquantitative analysis, using acridine ester labeling analysis technology and double antibody sandwich method. This method uses a two-step method (washing twice). First, the sample is reacted with the biotinylated hepatitis B virus surface antibody (Anti-HBs). If the sample contains HBsAg, it will form an antigen-antibody complex , Adding streptavidin-coated particles, the complex forms a solid phase under the interaction of biotin and streptavidin. Then the reaction solution is placed in a magnetic field, the magnetic particles under test will be adsorbed, and the unbound substances will be washed and removed by washing. Then add the acridine ester labeled Anti. HBs reacts with the HBsAg complex on the magnetic particles, and the unbound substance is washed and removed by washing. Finally, a chemiluminescence buffer is injected to detect the intensity of the chemiluminescence photons, and the light intensity generated is proportional to the concentration of HBsAg in the sample.

This method can be effectively applied to the clinical diagnosis of hepatitis B and the dynamic monitoring of the disease. It has the advantages of high sensitivity, good specificity, accurate quantification, and all performance indicators can meet the clinical needs. It is of great significance for the prevention and treatment of Hepatitis B.

References: Ou Saiying, Pan Yangbin, Chen Xiufa, Sha Lifeng, Liang Chen, etc. The establishment of a chemiluminescence quantitative immunoassay method for hepatitis B surface antigen acridinium ester [J] Labeled Immunoassay and Clinic, 2019, 26 (6): 152 -1056